Recently, the CRM1 inhibitor selinexor (44,45) has been approved by the FDA for the treatment of multiple myeloma, and the eIF4E inhibitor ribavirin has been shown to induce regression of aggressive B-cell lymphomas (46), both supporting the usability of cancer therapeutics targeting the CRM1 pathway. This evidence concerns the gene EIF4E and plasma cell myeloma.